On the contrary, increased PTPN1 was associated with significantly better OS, distant metastasis-free survival (DMSF), PPS, and recurrence-free survival (RFS) in patients with breast cancer, significantly better progression-free survival (PFS) in patients with ovarian cancer, and with a significantly better PPS in patients with gastric cancer (Supplementary Figure S6; P < 0.05 for all). Here, PTPN1 is linked to breast cancer.